Purpose of Review Active surveillance is now widely utilized for the management of low-risk prostate cancer (PCa). The limits of surveillance for men with intermediate risk cancer are controversial. While there is a broad consensus that men with low-risk disease can be safely managed with AS, many potential candidates, including those with Gleason 3 + 4 disease, PSA >10, younger men and African-Americans are often excluded. Recent Findings Outcome data for intermediate-risk patients managed by active surveillance demonstrate reasonable outcomes, but these men clearly are at higher risk for progression to metastatic disease. The use of biomarkers and multiparametric MRI will enable a more precise and personalized risk assessment. Literature describing the effects of young age on outcomes is limited, but the experience reported in prospective series with 15-20 year follow-up suggests it is a safe approach. African-American men are at greater risk for occult co-existent higher-grade disease, but in the absence of this their outcome is favorable. Summary Patients with intermediate-risk PCa should not be excluded from active surveillance based on a single criterion. Treatment decisions should be based on multiple parameters, including percent Gleason 4, PSA density, cancer volume on biopsy, MRI findings, and patient age and co-morbidity.
Introduction
Once considered heresy, it is now widely accepted that many patients with prostate cancer can be managed conservatively, with periodic monitoring to identify those who should be reclassified and offered treatment. The primary parameter for identifying patients at low risk of progression to metastasis is Gleason score, i.e., patients in Grade Group 1 (Gleason pattern 3). The potential benefits of conservative management are compelling, and raise the obvious question: are there intermediate-risk patients who can also be safely offered surveillance as an initial management strategy? The answer is clearly yes; the challenge is to identify them accurately. The risks of progression to metastasis are greater in patients who harbor Gleason 4 pattern, so the stakes are higher. .
The evidence to support conservative management for some intermediate-risk patients is derived from epidemiologic data, randomized trials, and prospective cohorts of such patients managed with surveillance. The limitations and risks of this approach can also be defined from these studies.
The dilemma for management of clinically localized prostate cancer emerges from the heterogeneity of the disease. Prostate cancer arises from genetically altered prostate epithelium and in most cases slowly progresses for many decades. Autopsy data has shown that about a third of men in their 30s and 40s have prostate cancers. The median age at diagnosis in North America is 67. This discrepancy clearly emphasizes the long trajectory from inception to clinical cancer (including a rise in PSA) in most men. Occasionally, however, young men are found to have aggressive, rapidly progressive disease. Thus prostate cancer natural history is difficult to predict with precision.
Based on autopsy studies, the majority of men who have prostate cancer live their natural life without having any symptoms [1•]. Zlotta [2] confirmed this hypothesis when prospectively compared tissue obtained during autopsy from prostate glands on a Caucasian and Asian population. PCa was found in a similar proportion (35%) on both groups. More than 50% of cancer in the Asian group had a Gleason score 7 or greater! The natural history of this disease characterized by slow progression (including Gleason 7) allows active surveillance (AS) to be an effective management strategy. It is clear from the autopsy data that many men who harbor intermediate risk disease (Gleason 7) are never diagnosed, and therefore have "clinically insignificant" cancer. The problem, of course, is that in some patients (a minority) it is a very significant cancer.
Randomized Trials
Three randomized trials provide information on the benefit of immediate treatment (radical prostatectomy) versus conservative treatment for patients with localized PCa. The Prostate Cancer Intervention Versus Observation Trial (PIVOT) randomly assigned 731 men with PCa to radical prostatectomy or observation. During the median follow-up of 12 years, the group treated by surgical intervention (47%) did not significantly reduce all cause or prostate cancer mortality, as compared with observation (49%) [3] . The second large study is the Scandinavian Prostate Cancer Group-4 randomized clinical trial. This prospective study compared radical prostatectomy versus watchful waiting (WW) in early prostate cancer. After 18 years of follow-up, overall mortality rates and prostate cancer-specific mortality were higher in patients managed with WW than in those with immediate treatment [4] . Crucially, neither used an "expectant management" approach with treatment if there was evidence of progression. Therefore, the generalizability of this study to the active surveillance scenario is limited.
Lastly, the Prostate Testing for Cancer and Treatment (ProtecT) trial compared three modalities of management (active monitoring, radical prostatectomy, and external-beam radiotherapy) on patients with localized PCa [5••] . Patients randomized to AS had a PSA monitored every 3 months during the first years and 6 months thereafter. Median follow-up was 10 years. From the 2664 patients with diagnosis of PCa, there were 17 prostate cancer-specific deaths overall (8, 5 , and 4 in the AS, surgery, and radiotherapy group, respectively) demonstrating there was no significant difference in the 10-year cancer-specific survival or overall survival rates. There was a difference in metastasis rate favoring radical treatment. This likely reflects the 25% of the cohort who had intermediate or high-risk disease, for whom conservative management is clearly associated with an increased risk of progression. Nonetheless, the lack of a mortality difference emphasizes that the majority of Gleason 7 patients are not at risk for prostate cancer death in the 10-year time frame.
Prospective Surveillance Trials Table 1 lists the various selection criteria for the five largest prospective surveillance cohorts. Most groups were restricted eligibility to Gleason 6, in some cases with no more than 2 cores involved and no more than 50% of any core involved. Two groups, Sunnybrook (Toronto) and Royal Marsden (London UK), included intermediate-risk patients. In the Sunnybrook surveillance cohort, 22% were intermediate risk, with Gleason <3 + 4 and/or PSA 10-20 n/ml. One third of these men were < age 70. The analysis of this group has provided some important observations. Despite close monitoring and intervention for evidence of risk progression, the 15-year prostate cancer metastasis rate was 3.7 times higher in the intermediate risk group [11•] . This increase in risk was associated almost solely with the presence of Gleason 7 cancer at initial diagnosis. The HR for 15-year prostate cancer mortality for Gleason 3 + 4 compared to 3 + 3 was 4.0; for Gleason 4 + 3, it was 10.5. Amongst this group, the actuarial 15-year metastasis rate was at least 20% [12] . For most clinicians and patients, that is an unacceptably high rate of progression. Importantly, a PSA above 10 did not confer a significant increased risk of metastasis in the absence of Gleason pattern 4 cancer.
This experience was in the pre-MRI and biomarker era, and also reflected the learning curve of active surveillance over a The Royal Marsden group also took an inclusive approach to eligibility. Seven percent of their cohort had Gleason 7 disease. The presence of Gleason 7 disease was associated with a 3.4 greater likelihood of finding "adverse pathology" on subsequent biopsy. Other predictors were percent positive cores, PSAV >1 ng/ml per year, maximum percentage involvement of any single core, and low %fPSA [9] . Of the two prostate cancer deaths in their cohort, one was in a patient with Gleason 7 at baseline.
A limitation of many reports of conservative management of intermediate-risk disease is the relatively short duration of follow-up. It is a clear inference from the Toronto experience and the PROTECT study that prostate cancer mortality takes 10-15 years to become apparent. (It is likely that the increased metastasis rate in the PROTECT study in the "active monitoring" arm seen at 10 years will evolve into a PCSM difference with increased follow-up). UCSF [15, 16] reported no difference in biopsy progression or treatment rates between low and intermediate CAPRA score patients, albeit with 47 months of follow-up.
It is clear from these low mortality rate differences that many patients with intermediate-risk features are surveillance candidates. In particular, these are patients with low volume of disease, older age, and co-existent co-morbidities limiting their life expectancy [17] .
Eligibility criteria for active surveillance have been variable, from restrictive in the Hopkins cohort (Epstein criteria only, i.e., 1-2 cores of Gleason 6 with no core >50% involved, PSAD <0.15) to inclusive in the Toronto cohort (all Gleason 6 patients and Gleason 3 + 4, PSA <20). Because of the very favorable experience with Gleason 6 cancer, and the significantly higher rate of progression with Gleason 7 disease, most groups have now converged to a middle ground, offering surveillance to most Gleason 6 cases regardless of cancer volume, and being very selective about offering it to Gleason 7 patients. For example, current guidelines from Cancer Care Ontario, ASCO, the AUA, and NICE (UK) all promote surveillance as the primary therapy for low-risk patients, and selective use of surveillance for intermediate-risk patients ( Despite the more intensive assessment, younger age was associated with a lower risk of biopsy upgrade and progression. There were no differences with respect to treatment, adverse disease, or biochemical recurrence. Younger patients should be advised that intermediate-term outcomes are not worse, but that longer-term follow-up is needed. Thus, young patients can, in most cases, be managed conservatively but require long-term follow-up. 4. Race: African-American/Canadians: several studies have reported a higher rate of occult co-existent cancer in low-risk patients, as well as higher rates of biochemical recurrence after surgery [30] [31] [32] . However, one large recent study of the SEARCH database including 40% AfricanAmerican men with low-risk cancer showed no difference in pathological upstaging or biochemical recurrence, reinforcing the use of surveillance in these men [33] . 5. Genomic markers: as of the publication of this document, the three genetic tissue assays summarized below have been approved by the FDA for men with prostate cancer. None of these tests have yet been validated as providing substantial benefit in the active surveillance population. However, the "sweet spot" for molecular biomarkers is the otherwise favorable-risk patient with small amount of pattern 4 (Grade Group 2) on biopsy who prefers a conservative approach if possible. A low score on a validated molecular assay provides a great deal of reassurance about the safety of non-intervention.
Genomic Classifier This is a 22-marker genomic classifier (GC), based on RNA expression. GC had independent predictive value on multivariable analysis for predicting metastasis following prostatectomy, with a hazard ration (HR) of 1.5 for each 10% increase in score, and these results were validated in two separate prostatectomy cohorts. A high score on biopsy is associated with an increased risk of metastasis (HR 1.7 for each 10% increase in score) [34, 35] . Currently, all newly diagnosed surveillance candidates receive an MRI within the first year of diagnosis, and a targeted biopsy if an abnormality is identified. Tissue-based genetic biomarkers are used for those cases where a discrepancy exists between the histologic and MRI findings, and those cases where there is a higher index of suspicion for clinically significant disease. Examples include patients under age 50 with low-risk disease, or men with Gleason 7 with >10% pattern 4 who prefer expectant management if possible.
Caveats Clinicians managing patients on active surveillance should maintain a sense of humility about our ability to predict natural history over the long term. Thus, important exceptions exist where radical treatment may be warranted despite a "low risk" profile. These exceptions include those unusual cases of PSA q 3-4 mo., monitor kinetics, otherwise same MRI at enrollment -young men (<50) with extensive Gleason 6 disease. These are uncommon; most men under 50 found to have Gleason 6 (Grade group 1) cancer have small-volume disease. Extensive Gleason 6 cancer in a male under 50 may be a signal of biological instability, despite the low grade, and radical intervention may be warranted. Other clues, including PSA density, MRI, and biomarkers, should be employed to aid decision making in this challenging circumstance. Conclusion: active surveillance for low-risk prostate cancer represents a major advance in the management of prostate cancer. There are clearly patients at the favorable end of intermediate risk who also may benefit from conservative management. The presence of Gleason 4 pattern does, however, confer an increased risk of progression. The best candidates for surveillance in this group are those with <10-20% Gleason pattern 4 and a low PSA density (<0.15). Age and comorbidity also play a role. Genomic profiling and mp-MRI are valuable additions to decision making. A single borderline parameter (for example, a small percentage of Gleason 4) should not be determinative with respect to eligibility for surveillance.
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